MIM
CDAK

MetLife Investment Management’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

MetLife Investment Management’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,809
Closed -$111K – 2580
2021
Q3 		$111K Buy
+6,809
New +$122K ﹤0.01% 2396

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $863M AUM 30.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.44B AUM 23.16% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MetLife Investment Management's CDAK Position: Q4 2021 in Review

MetLife Investment Management sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q4 2021, closing a stake of 6,809 shares — an estimated $111K sold.

MetLife Investment Management first reported a position in CDAK in Q3 2021 and held it in 1 quarter. The position peaked at $111K in Q3 2021. 51 funds tracked by Wall St. Rank hold CDAK as of Q4 2021.

  • MetLife Investment Management reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • MetLife Investment Management sold 6,809 Codiak BioSciences, Inc. Common Stock shares in Q4 2021, an estimated $111K.
  • MetLife Investment Management first reported a position in Codiak BioSciences, Inc. Common Stock in Q3 2021 and held it in 1 quarter.
  • MetLife Investment Management's Codiak BioSciences, Inc. Common Stock position peaked at $111K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q4 2021.

Based on MetLife Investment Management's 13F filing for Q4 2021, filed 15 Feb 2022.